Key result
Trastuzumab induces reversible takotsubo cardiomyopathy presenting with an LVEF of 38%.
Why the study?
Trastuzumab used in chemotherapy for breast cancer is known to cause myocardial injury, but takotsubo cardiomyopathy during trastuzumab treatment is rare and not well reported.
Trastuzumab therapy can rarely induce takotsubo cardiomyopathy, which appears reversible upon discontinuation of the offending agent.
Answers are grounded in this paper and cite their sources.
Trastuzumab may trigger reversible takotsubo cardiomyopathy; this Level 5 case leaves open whether apical ballooning warrants specific surveillance protocols.
乳癌に対する化学療法として用いられるトラスツズマブ(trastuzumab: TRZ)は副作用に心筋障害が知られている.今回我々はTRZ投与中にたこつぼ型心筋症を発症した症例を経験したので報告する.症例は58歳,女性.200X‐2年11月に左乳癌と診断され乳房切除術を施行された.その後,術後補助化学療法を開始され,200X‐1年5月よりTRZが投与された.200X年8月,左室駆出率は38%と低下し,たこつぼ型心筋症様の壁運動異常を認めた.TRZを中止し経過観察したところ壁運動異常は改善した.TRZによる心筋障害は用量に依存せず,1‐4%に症候性心不全,10%に左室駆出率低下を認めるとされる.TRZ投与中にたこつぼ型心筋症を発症した症例はまれであり,報告する.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2014) studied this question. Trastuzumab chemotherapy induced a rare case of takotsubo cardiomyopathy with a left ventricular ejection fraction of 38%, which improved after the medication was discontinued.
Synapse has enriched 10 related papers. Consider them for comparative context: